Please ensure Javascript is enabled for purposes of website accessibility

3 Big Hints That COVID Vaccine Booster Doses Are on the Way

By Keith Speights – Jul 28, 2021 at 5:52AM

Key Points

  • The official stance of both the CDC and FDA is still that third booster doses of COVID-19 vaccines aren't needed.
  • However, there are several reasons to think that booster doses will be authorized in the U.S. in the not-too-distant future for immunocompromised individuals.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The writing could already be on the wall.

It wasn't long ago that the U.S. government appeared to be butting heads with top COVID-19 vaccine makers over the need for booster doses. On July 8, the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA) issued a joint statement about booster doses. That statement seemed to slap down Pfizer (PFE 0.51%) and Moderna (MRNA 2.53%), both of which had publicly voiced views that booster shots would probably be needed.

Neither the CDC nor the FDA has changed their official stances on booster doses. But now, it looks like Pfizer and Moderna might have been right all along. Here are three big hints that COVID vaccine booster doses are on the way -- at least for some people.

A masked healthcare professional administering a shot.

Image source: Getty Images.

1. Fauci thinks boosters are likely

Dr. Anthony Fauci is well known to most Americans by now. He's director of the U.S. National Institute of Allergy and Infectious Diseases and serves as the chief medical advisor to President Biden. 

On Sunday, Fauci stated in an interview with CNN that a third COVID-19 booster dose "might likely happen." He indicated that immunocompromised individuals would be most likely to receive a booster.

Fauci doesn't make the decision about boosters himself. However, he's heavily involved with the ongoing discussions about matters related to the COVID-19 pandemic. It's a pretty good bet that his view reflects a growing consensus among federal healthcare experts.

Last week, the CDC's Advisory Committee on Immunization Practices (ACIP) met to discuss booster doses. The committee didn't make an official recommendation to the CDC. However, its members seemed to be largely supportive of allowing immunocompromised individuals to receive a third booster dose if recommended by their doctors. 

2. Other countries' precedents

Israel was the first to begin giving third booster doses of the Pfizer-BioNTech vaccine to some immunocompromised individuals earlier this month. The country is also now evaluating the possibility of giving a third shot to individuals over age 60 in hopes of preventing another wave of lockdowns. 

France quickly followed suit. On July 12, President Emmanuel Macron announced that booster doses would be administered to older individuals and immunocompromised individuals as well as hospital staff over age 50 who work with patients most vulnerable to COVID-19. 

The U.S. doesn't have to follow in the footsteps of what other countries do in their fight against COVID-19. However, there's no question that federal healthcare officials here pay attention to what other nations are doing.  

3. Uncle Sam's big new vaccine order

Last week, Pfizer and BioNTech announced that the U.S. government was purchasing another 200 million doses of their COVID-19 vaccine. Why could this be a hint that booster doses are on the way? Follow the numbers.

Prior to this latest deal, the U.S. had already secured supply deals with Pfizer-BioNTech, Moderna, and Johnson & Johnson for enough doses to fully vaccinate 600 million individuals. The entire U.S. population, including children, totals around 333 million.

We haven't included the 100 million doses that the U.S. will receive from Novavax if its COVID-19 vaccine wins emergency use authorization. Nor have we counted the 300 million doses that the U.S. ordered from AstraZeneca or the 500 million doses purchased from Pfizer to donate to poor countries. 

Why would Uncle Sam need even more doses of the Pfizer-BioNTech vaccine? The most likely reason: booster doses.

What it could mean for vaccine stocks

Vaccine stocks obviously benefit when more doses are sold. However, don't necessarily expect the shares of Pfizer, Moderna, or any of the other leading vaccine makers to skyrocket if the U.S. officially decides to give third booster shots.

For one thing, it's most likely that the booster doses would only be authorized (at least initially) for immunocompromised individuals. More importantly, though, as we've already seen, the U.S. already has enough vaccine doses ordered that it probably won't need too many more -- at least not in the near future.

Keith Speights owns shares of Pfizer. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
$49.46 (0.51%) $0.25
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.78 (0.93%) $0.61
Johnson & Johnson Stock Quote
Johnson & Johnson
$177.31 (0.04%) $0.07
Novavax Stock Quote
$17.06 (3.14%) $0.52
Moderna Inc. Stock Quote
Moderna Inc.
$180.86 (2.53%) $4.46
BioNTech SE Stock Quote
BioNTech SE
$164.80 (6.43%) $9.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.